Table 3.
Comparisons between high-bilirubin and low-bilirubin patients in this study
| Parameters | High-bilirubin (n = 29) | Low-bilirubin (n = 48) | Statistical values | P |
|---|---|---|---|---|
| Female | 14 (47) | 27 (56) | 0.346 | |
| Age (years) | 55 ± 14 | 58 ± 11 | −0.257* | 0.798 |
| WHO Functional Class | ||||
| WHO FC I–II | 11 (38) | 26 (54) | 0.239 | |
| WHO FC III–IV | 18 (62) | 22 (46) | ||
| Biomarker | ||||
| ALT (U/L) | 26.4 (16.0, 34.0) | 28.0 (18.3, 30.0) | 689.5† | 0.945 |
| AST (U/L) | 31.6 (21.0, 39.0) | 28.3 (17.3, 33.0) | 540.0† | 0.101 |
| GGT (U/L) | 97.3 (44.5, 131.0) | 67.4 (34.5, 79.3) | 460.0† | 0.013 |
| Uric acid (mmol/L) | 377 ± 180 | 354 ± 115 | –0.974* | 0.335 |
| NT-proBNP (pg/ml) | 2872 (730, 4665) | 1776 (649, 2761) | 521.5† | 0.067 |
| Hemodynamic and exercise capacity | ||||
| 6MWD | 262 ± 98 | 358 ± 90 | 4.410* | 0.000 |
| CVP (mmHg) | 10.8 ± 6.0 | 7.1 ± 4.4 | −2.815* | 0.000 |
| sPAP (mmHg) | 91 ± 17 | 84 ± 17 | −1.322* | 0.190 |
| mPAP (mmHg) | 52 ± 11 | 49 ± 10 | −1.326* | 0.189 |
| PVR (woods units) | 16.35 ± 7.61 | 13.08 ± 5.23 | −2.073* | 0.042 |
Data are shown as n (%), mean ± SD or median (IQR). P values were calculated by independent samples t-test, Mann–Whitney U-test or Fisher’s exact test. Hyperbilirubinemia means a serum concentration of total bilirubin ≥23.7 μmol/L, and normal bilirubinemia means a serum concentration of total bilirubin <23.7 μmol/L. *t values; †U values. WHO FC: World Health Organization functional class; ALT: Alanine transaminase; AST: Aspartate transaminase; GGT: Gamma-glutamyl transpeptidase; NT-proBNP: N-terminal pro-peptide of brain natriuretic peptide; 6WMD: 6-min walk distance; CVP: Central venous pressure; sPAP: Systolic pulmonary artery pressure; mPAP: Medium pulmonary artery pressure; PVR: Pulmonary vascular resistance; IQR: Interquartile range; SD: Standard deviation.